Abstract
The androgen receptor inhibitor darolutamide (Nubeqa – Bayer) has been approved by the FDA for use in combination with docetaxel for treatment of metastatic hormone-sensitive prostate cancer (mHSPC).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have